Dana Investment Advisors Inc. Increases Stock Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Dana Investment Advisors Inc. boosted its position in IQVIA Holdings Inc. (NYSE:IQV) by 7.4% in the second quarter, HoldingsChannel reports. The firm owned 87,145 shares of the medical research company’s stock after buying an additional 6,019 shares during the quarter. Dana Investment Advisors Inc.’s holdings in IQVIA were worth $18,426,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of the business. First Foundation Advisors grew its stake in shares of IQVIA by 3.8% during the 2nd quarter. First Foundation Advisors now owns 1,161 shares of the medical research company’s stock worth $245,000 after acquiring an additional 43 shares during the period. Team Hewins LLC grew its stake in IQVIA by 5.0% in the 1st quarter. Team Hewins LLC now owns 973 shares of the medical research company’s stock valued at $246,000 after buying an additional 46 shares in the last quarter. Invera Wealth Advisors LLC raised its holdings in IQVIA by 0.3% during the 2nd quarter. Invera Wealth Advisors LLC now owns 14,506 shares of the medical research company’s stock valued at $3,183,000 after acquiring an additional 46 shares during the period. Covestor Ltd boosted its holdings in shares of IQVIA by 45.3% in the first quarter. Covestor Ltd now owns 154 shares of the medical research company’s stock worth $39,000 after acquiring an additional 48 shares during the period. Finally, Oregon Public Employees Retirement Fund grew its position in shares of IQVIA by 0.3% in the second quarter. Oregon Public Employees Retirement Fund now owns 15,668 shares of the medical research company’s stock valued at $3,313,000 after purchasing an additional 48 shares in the last quarter. 89.62% of the stock is owned by institutional investors.

IQVIA Trading Up 0.9 %

NYSE IQV opened at $236.97 on Tuesday. The stock has a 50-day moving average of $241.32 and a 200-day moving average of $233.07. The company has a current ratio of 0.85, a quick ratio of 0.85 and a debt-to-equity ratio of 1.80. IQVIA Holdings Inc. has a 1-year low of $167.42 and a 1-year high of $261.73. The firm has a market cap of $43.20 billion, a PE ratio of 32.37, a price-to-earnings-growth ratio of 2.25 and a beta of 1.49.

IQVIA (NYSE:IQV) last issued its earnings results on Monday, July 22nd. The medical research company reported $2.64 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.57 by $0.07. IQVIA had a net margin of 9.39% and a return on equity of 28.59%. The firm had revenue of $3.81 billion for the quarter, compared to analysts’ expectations of $3.79 billion. During the same quarter last year, the business earned $2.22 earnings per share. The business’s revenue was up 2.3% on a year-over-year basis. As a group, sell-side analysts forecast that IQVIA Holdings Inc. will post 10.25 EPS for the current year.

Analysts Set New Price Targets

A number of research firms have weighed in on IQV. Barclays lifted their target price on IQVIA from $255.00 to $275.00 and gave the company an “overweight” rating in a report on Tuesday, July 23rd. Evercore ISI raised their price target on shares of IQVIA from $230.00 to $270.00 and gave the company an “outperform” rating in a report on Tuesday, July 23rd. Royal Bank of Canada began coverage on shares of IQVIA in a report on Wednesday, September 4th. They issued an “outperform” rating and a $275.00 price target on the stock. Robert W. Baird upped their target price on IQVIA from $251.00 to $256.00 and gave the stock a “neutral” rating in a research note on Friday, September 20th. Finally, StockNews.com cut shares of IQVIA from a “buy” rating to a “hold” rating in a research report on Friday. Five research analysts have rated the stock with a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, IQVIA has an average rating of “Moderate Buy” and a consensus target price of $267.00.

Insider Buying and Selling at IQVIA

In other news, insider Eric Sherbet sold 1,300 shares of the stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of $246.33, for a total transaction of $320,229.00. Following the completion of the sale, the insider now directly owns 19,536 shares in the company, valued at $4,812,302.88. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Corporate insiders own 1.60% of the company’s stock.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.